Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Opioidien käyttöhäiriön farmakoterapian (RDD) säilyttämistä, kestoa ja lopettamista koskevien strategioiden optimointi

maanantai 9. marraskuuta 2026 päivittänyt: NYU Langone Health

NIDA-CTN-0100: Opioidien käytön häiriön farmakoterapian (RDD) säilyttämisen, keston ja lopettamisen strategioiden optimointi

This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.

Tutkimuksen yleiskatsaus

Tila

Aktiivinen, ei rekrytointi

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

The main objectives of this study are:

  1. To test strategies to improve retention in treatment on medications for opioid use disorder (MOUD), among patients initiating treatment for OUD.
  2. To test strategies to improve outcomes among patients who have achieved stable remission on MOUD and want to discontinue MOUD.
  3. To develop models to predict who is able to discontinue MOUD without relapse, based on patient characteristics, including duration of MOUD prior to discontinuation.

The study will have a multicenter, randomized, pragmatic non-blinded design. The study has two phases, a Retention Phase and a Discontinuation Phase.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

1516

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Arkansas
      • Little Rock, Arkansas, Yhdysvallat, 72205
        • University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)
    • California
      • Tarzana, California, Yhdysvallat, 91356
        • Tarzana Treatment Centers, Inc.
    • Connecticut
      • Bridgeport, Connecticut, Yhdysvallat, 06610
        • Liberation Programs, Inc.
    • Florida
      • Clearwater, Florida, Yhdysvallat, 33760
        • Operation PAR
      • Jacksonville, Florida, Yhdysvallat, 32204
        • Gateway Community Services
      • Orlando, Florida, Yhdysvallat, 32806
        • Aspire Health Partners
    • Maryland
      • Baltimore, Maryland, Yhdysvallat, 21229
        • Mountain Manor / Maryland Treatment Centers
    • Massachusetts
      • Belmont, Massachusetts, Yhdysvallat, 02478
        • McLean Hospital
      • Fall River, Massachusetts, Yhdysvallat, 02720
        • Stanley Street Treatment and Resources, Inc.
      • Newton, Massachusetts, Yhdysvallat, 02458
        • Square Medical Group, LLC
    • Missouri
      • Cape Girardeau, Missouri, Yhdysvallat, 63703
        • Gibson Center for Behavioral Change
    • New Hampshire
      • Lebanon, New Hampshire, Yhdysvallat, 03766
        • Dartmouth Hitchcock - ATP
    • New Mexico
      • Albuquerque, New Mexico, Yhdysvallat, 87106
        • University of New Mexico Addiction and Substance Abuse Program
    • New York
      • New York, New York, Yhdysvallat, 10016
        • Bellevue Hospital Center
    • Oregon
      • Roseburg, Oregon, Yhdysvallat, 97470
        • Adapt Integrated Health Care
      • Winston, Oregon, Yhdysvallat, 97496
        • Adapt Integrated Health Care
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Yhdysvallat, 15213
        • Center for Psychiatric and Chemical Dependency Services (CPCDS)
      • Pittsburgh, Pennsylvania, Yhdysvallat, 15219
        • Internal Medicine Recovery Engagement Program (IM-REP)
    • South Carolina
      • Conway, South Carolina, Yhdysvallat, 29526
        • Shoreline Behavioral Health Services
    • Utah
      • Salt Lake City, Utah, Yhdysvallat, 84108
        • Huntsman Mental Health Institute / University of Utah
    • West Virginia
      • Morgantown, West Virginia, Yhdysvallat, 26505
        • Chestnut Ridge Center

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria for Retention Phase:

  1. 18 years of age or older;
  2. Meet DSM-5 criteria for current opioid use disorder (heroin, fentanyl or other synthetic opioids, and/or prescription opioids);
  3. Seeking treatment for opioid use disorder and choosing either buprenorphine (BUP) or extended-release injection naltrexone (XR-NTX);
  4. If choosing buprenorphine, willing to be randomized to SL-BUP-16mg, SL-BUP-32mg, or XR-BUP;
  5. Willing to be randomized to either MM (standard Medical Management plus counseling treatment as usual available at the site) or MMR (MM plus usual counseling and access to an app delivering CM + CBT);
  6. In good-enough general health (meaning good enough health to be in outpatient treatment) as determined by the study medical clinician on the basis of medical history, review of systems, and physical/mental status exam, to permit treatment with XR-NTX or BUP;
  7. Willing and able to provide written informed consent;
  8. Able to speak English sufficiently to understand the study procedures;
  9. If female of childbearing potential, willing to practice an effective method of birth control for the duration of participation in the study (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).

Exclusion Criteria for Retention Phase:

  1. Serious medical, psychiatric, or co-occurring substance use disorder or concomitant medication that, in the opinion of the study medical clinician, makes the patient not appropriate for outpatient treatment with buprenorphine or XR-NTX, but instead requires a higher or different level of care. Examples include:

    1. Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
    2. Severe, untreated or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
    3. Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use, requiring a different level of care (e.g., hospitalization);
  2. Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);

  3. Known allergy or sensitivity to preferred medication or its components;

  4. Maintenance on methadone at the time of signing consent;

  5. For those preferring XR-NTX, presence of pain of sufficient severity as to require ongoing pain management with opioids;

  6. For those preferring XR-NTX, body habitus that, in the judgment of the study physician, precludes safe intramuscular injection of XR-NTX (e.g., BMI>40, excess fat tissue over the buttocks, emaciation);

  7. If female, currently pregnant or breastfeeding or planning on conception;

  8. Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;

  9. Have used the reSET-O or CHESS Connections mHealth apps in the 3 months prior to consent;

  10. Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area).

Inclusion Criteria for Discontinuation Phase:

  1. 18 years of age or older;
  2. Have been receiving buprenorphine for OUD for at least the past year or XR-NTX pharmacotherapy for OUD for at least the past 6 months prior to consent for the Discontinuation Phase;
  3. Express the desire to discontinue MOUD after a shared decision-making discussion with the treating provider;
  4. Meet stability criteria, i.e., have abstained from opioids (other than buprenorphine), cocaine, methamphetamine, and non-prescribed benzodiazepines for the past ≥12 weeks, and do not meet DSM-5 criteria for current (≥12 weeks) alcohol use disorder (participants with cannabis use will be eligible);
  5. If currently taking buprenorphine, are willing to take either SL-BUP or XR-BUP if randomized to that condition;
  6. Willing to be randomized to either MM or to MMD;
  7. Able to provide written informed consent after discussion with their provider regarding the risks of discontinuation;
  8. Able to speak English sufficiently to understand the study procedures;
  9. If female of childbearing potential, willing to practice an effective method of birth control while in the study and taking study medication (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).

Exclusion Criteria for Discontinuation Phase:

  1. Serious medical or psychiatric disorder or concomitant medication that, in the opinion of the study medical clinician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include:

    1. Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
    2. Severe, untreated, or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
  2. Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);

  3. For participants entering the study taking buprenorphine, presence of pain requiring or likely requiring ongoing pain management with buprenorphine or other opioids;

  4. If female, currently pregnant or breastfeeding or planning on conception;

  5. Use of opioids (other than buprenorphine), cocaine, methamphetamine, or non-prescribed benzodiazepines in the past 12 weeks;

  6. Meets current DSM-5 criteria for any current alcohol use disorder;

  7. Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;

  8. Have used the Connections mHealth app in the 3 months prior to consent (other than Connections in the Retention Phase);

  9. Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Tehtävätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Retention: SL-BUP standard dose + MM

Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

Muut nimet:
  • Suboxone
  • sublingvaalinen buprenorfiini

MM consists of standard Medical Management and the usual counseling at the treatment program.

Kokeellinen: Retention: SL-BUP high dose + MM

High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

Muut nimet:
  • Suboxone
  • sublingvaalinen buprenorfiini

MM consists of standard Medical Management and the usual counseling at the treatment program.

Kokeellinen: Retention: XR-BUP + MM

Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

Muut nimet:
  • CAM2038
  • pitkitetysti vapauttava buprenorfiini
  • Brixadi
Kokeellinen: Retention: XR-NTX + MM

Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Monthly dosing of extended-release injectable naltrexone

Muut nimet:
  • Vivitrol
  • pitkitetysti vapauttava naltreksoni
Kokeellinen: Retention: SL-BUP standard dose + MMR

Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

Muut nimet:
  • Suboxone
  • sublingvaalinen buprenorfiini

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Kokeellinen: Retention: SL-BUP high dose + MMR

High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

Muut nimet:
  • Suboxone
  • sublingvaalinen buprenorfiini

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Kokeellinen: Retention: XR-BUP + MMR

Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

Muut nimet:
  • CAM2038
  • pitkitetysti vapauttava buprenorfiini
  • Brixadi

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Kokeellinen: Retention: XR-NTX + MMR

Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Monthly dosing of extended-release injectable naltrexone

Muut nimet:
  • Vivitrol
  • pitkitetysti vapauttava naltreksoni

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Kokeellinen: Discontinuation: Discontinue SL-BUP with SL-BUP + MM

Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

Muut nimet:
  • Suboxone
  • sublingvaalinen buprenorfiini

MM consists of standard Medical Management and the usual counseling at the treatment program.

Kokeellinen: Discontinuation: Discontinue SL-BUP with XR-BUP + MM

Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

Muut nimet:
  • CAM2038
  • pitkitetysti vapauttava buprenorfiini
  • Brixadi
Kokeellinen: Discontinuation: Discontinue XR-BUP with XR-BUP + MM

Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

Muut nimet:
  • CAM2038
  • pitkitetysti vapauttava buprenorfiini
  • Brixadi
Kokeellinen: Discontinuation: Discontinue XR-NTX with XR-NTX + MM

Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Monthly dosing of extended-release injectable naltrexone

Muut nimet:
  • Vivitrol
  • pitkitetysti vapauttava naltreksoni
Kokeellinen: Discontinuation: Discontinue SL-BUP with SL-BUP + MMD

Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

Muut nimet:
  • Suboxone
  • sublingvaalinen buprenorfiini

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Kokeellinen: Discontinuation: Discontinue SL-BUP with XR-BUP + MMD

Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

Muut nimet:
  • CAM2038
  • pitkitetysti vapauttava buprenorfiini
  • Brixadi

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Kokeellinen: Discontinuation: Discontinue XR-BUP with XR-BUP + MMD

Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

Muut nimet:
  • CAM2038
  • pitkitetysti vapauttava buprenorfiini
  • Brixadi

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Kokeellinen: Discontinuation: Discontinue XR-NTX with XR-NTX + MMD

Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Monthly dosing of extended-release injectable naltrexone

Muut nimet:
  • Vivitrol
  • pitkitetysti vapauttava naltreksoni

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Retention: Continuous retention in MOUD treatment through 26 weeks
Aikaikkuna: Retention: from randomization through week 26

Binary (yes/no). Continuously enrolled in maintenance treatment on one or more of the evidence-based MOUD modalities (e.g., SL-BUP, XR-BUP, XR-NTX, or methadone maintenance) with no more than a 28-day gap on MOUD over the 26-week period.

Retention: from randomization through week 26
Discontinuation: Completed Discontinuation without Relapse
Aikaikkuna: Discontinuation: from randomization through week 24 follow up

Binary (yes/no). Discontinuing MOUD during the taper period, no return to MOUD, and no relapse to opioid use, either during the taper (up to 48 weeks for those entering on BUP or 24 weeks for those entering on XR-NTX) or during the 24 weeks after MOUD is discontinued.

Discontinuation: from randomization through week 24 follow up

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Retention KS1: Weekly opioid abstinence
Aikaikkuna: Retention: from randomization through week 26

Weekly opioid abstinence (measured by Timeline Followback, not contradicted by toxicology test). Repeated yes/no measure for each of weeks 1 through 26.

Retention: from randomization through week 26
Retention KS2: Treatment effectiveness
Aikaikkuna: Retention: at week 26

Retention treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 26.

Retention: at week 26
Retention KS3: Treatment by baseline severity
Aikaikkuna: Retention: at week 26

Treatment by baseline severity interaction where severity is indicated by the randomization stratum injection use (yes/no).

Retention: at week 26
Discontinuation KS1: Completed Discontinuation
Aikaikkuna: Discontinuation: from randomization through week 24 follow up

Completed Discontinuation without regard to relapse status

Discontinuation: from randomization through week 24 follow up
Discontinuation KS2: Relapse
Aikaikkuna: Discontinuation: from randomization through week 24 follow up

Relapse - separate binary outcome without regard to discontinuation status

Discontinuation: from randomization through week 24 follow up
Discontinuation KS3: Safety
Aikaikkuna: Discontinuation: from randomization through week 24 follow up

Safety outcomes (binary, any one or more occurrences): overdoses, all non-fatal plus fatal.

Discontinuation: from randomization through week 24 follow up
Discontinuation KS4: Treatment effectiveness
Aikaikkuna: Discontinuation: at end of taper (EoT) and week 24 follow up

Discontinuation treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 24. Measured at the end of taper (EOT): up to 24 weeks for tapers with XR-NTX and up to 48 weeks for tapers with BUP; and at the week 24 follow up (primary outcome timepoint).

Discontinuation: at end of taper (EoT) and week 24 follow up

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Edward V Nunes, MD, New York State Psychiatric Institute/Columbia University Irving Medical Center
  • Päätutkija: Roger Weiss, MD, Harvard Medical School/McLean Hospital
  • Päätutkija: John Rotrosen, MD, NYU Langone Health

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 8. kesäkuuta 2021

Ensisijainen valmistuminen (Arvioitu)

Torstai 31. joulukuuta 2026

Opintojen valmistuminen (Arvioitu)

Sunnuntai 31. tammikuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 29. kesäkuuta 2020

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 6. heinäkuuta 2020

Ensimmäinen Lähetetty (Todellinen)

Torstai 9. heinäkuuta 2020

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 10. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 9. marraskuuta 2026

Viimeksi vahvistettu

Keskiviikko 1. heinäkuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • 19-01363
  • UG1DA015831 (Yhdysvaltain NIH-apuraha/sopimus)
  • CTN-0100 (Muu tunniste: NIDA Clinical Trials Network)
  • UG1DA013035 (Yhdysvaltain NIH-apuraha/sopimus)
  • 20-PRS-057 (Muu tunniste: Biomedical Research Alliance of New York (BRANY) sIRB)
  • 146193 (Muu tunniste: FDA/IND#)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

This study will comply with the NIH Data Sharing Policy and Implementation Guidance (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm) and (for HEAL-funded studies) the HEAL Public Access and Data Sharing Policy (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/research/heal-public-access-data-sharing-policy).

Primary data for this study will be available to the public in the NIDA data repository. For more details on data sharing please visit https://datashare.nida.nih.gov/.

The primary outcome(s) publication will be included along with study underlying primary data in the data share repository, and it will also be deposited in PubMed Central http://www.pubmedcentral.nih.gov/ per NIH Policy (http://publicaccess.nih.gov/).

IPD-jaon aikakehys

Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .